Zentrum für Kinder- und JugendmedizinKinderklinik

Teilnahme an klinischen Studien

Neben der Initiierung und Durchführung eigener Forschungsprojekte nehmen als Studienzentrum an zahlreichen multizentrischen klinischen Studien teil:

HARMONIE (NCT05437510)

The purpose of this study is to determine the efficacy and safety of a single intramuscular (IM) dose of nirsevimab, compared to no intervention, for the prevention of hospitalizations due to lower respiratory tract infection (LRTI) caused by confirmed RSV infection (henceforth referred to as RSV LRTI hospitalizations) in all infants under 12 months of age who are not eligible to receive palivizumab.

SHP607 (Footprint)

The purpose of this study is to determine if an investigational drug (IGF-1) can reduce the burden of chronic lung disease in extremely premature babies through 12 months corrected age (CA), as compared to extremely premature babies receiving standard neonatal care alone

COSGOD

The aim of the COSGOD Phase III trial is to examine, if it is possible to increase survival without cerebral injury in preterm neonates <32 weeks of gestation by monitoring the cerebral tissue oxygen saturation in addition to routine monitoring of arterial oxygen saturation and heart rate and specified clinical treatment guidelines during immediate transition period after birth (the first 15 minutes).

NeoVitA

Prospektive, multizentrische, doppelblinde, placebo-kontrollierte Phase-3 Studie zur Evaluation der Effektivität von früher postnataler zusätzlicher hochdosierter oraler Vitamin A-Supplementierung (5000 IU/kg/d) versus Placebo für die Dauer von 28 Tagen zur Prävention der bronchopulmonalen Dysplasie (BPD) oder Tod bei extrem kleinen Frühgeborenenen (ELBW).

SafeBoosC

The primary objective of the trial is to examine if it is possible to stabilise the cerebral oxygenation of extremely preterm infants during the first 72 hours of life through the application of cerebral NIRS oximetry and implementation of an rStO2-specific clinical treatment guideline. We hypothesise that by using the specified treatment guideline to respond to cerebral monitoring readings outside the target range, we would reduce the burden of hypo- and hyperoxia and consequently reduce brain injury.